Miners J O, Yang X, Knights K M, Zhang L
Department of Clinical Pharmacology and Flinders Centre for Innovation in Cancer, Flinders University School of Medicine, Adelaide, South Australia, Australia.
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Clin Pharmacol Ther. 2017 Sep;102(3):436-449. doi: 10.1002/cpt.757. Epub 2017 Jul 26.
Recent advances in the identification and characterization of renal drug transporters and drug-metabolizing enzymes has led to greater understanding of their roles in drug and chemical elimination and in modulation of the intrarenal exposure and response to drugs, nephrotoxic compounds, and physiological mediators. Furthermore, there is increasing awareness of the potential importance of drug-drug interactions (DDIs) arising from inhibition of renal transporters, and regulatory agencies now provide recommendations for the evaluation of transporter-mediated DDIs. Apart from the well-recognized effects of kidney disease on renal drug clearance, there is a growing body of evidence demonstrating that the nonrenal clearances of drugs eliminated by certain transporters and drug-metabolizing enzymes are decreased in patients with chronic kidney disease (CKD). Based on these observations, renal impairment guidance documents of regulatory agencies recommend pharmacokinetic characterization of both renally cleared and nonrenally cleared drugs in CKD patients to inform possible dosage adjustment.
肾脏药物转运体和药物代谢酶的识别与表征方面的最新进展,使人们对它们在药物和化学物质消除以及调节肾内药物暴露和对药物、肾毒性化合物及生理介质的反应中的作用有了更深入的了解。此外,人们越来越意识到由肾脏转运体抑制引起的药物相互作用(DDIs)的潜在重要性,监管机构现在为评估转运体介导的DDIs提供了建议。除了众所周知的肾脏疾病对肾药物清除率的影响外,越来越多的证据表明,慢性肾脏病(CKD)患者中,某些转运体和药物代谢酶消除的药物的非肾清除率降低。基于这些观察结果,监管机构的肾功能损害指导文件建议对CKD患者中经肾清除和非经肾清除的药物进行药代动力学表征,以为可能的剂量调整提供依据。